DE69518839T2 - Mehrschichtige pharmazeutische dosierungsform mit kontrollierter freigabe - Google Patents

Mehrschichtige pharmazeutische dosierungsform mit kontrollierter freigabe

Info

Publication number
DE69518839T2
DE69518839T2 DE69518839T DE69518839T DE69518839T2 DE 69518839 T2 DE69518839 T2 DE 69518839T2 DE 69518839 T DE69518839 T DE 69518839T DE 69518839 T DE69518839 T DE 69518839T DE 69518839 T2 DE69518839 T2 DE 69518839T2
Authority
DE
Germany
Prior art keywords
dosage form
controlled release
drug
pharmaceutical dosage
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69518839T
Other languages
English (en)
Other versions
DE69518839D1 (de
Inventor
M Kotwal
A Howard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of DE69518839D1 publication Critical patent/DE69518839D1/de
Application granted granted Critical
Publication of DE69518839T2 publication Critical patent/DE69518839T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
DE69518839T 1994-03-23 1995-03-16 Mehrschichtige pharmazeutische dosierungsform mit kontrollierter freigabe Expired - Lifetime DE69518839T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/217,331 US5395626A (en) 1994-03-23 1994-03-23 Multilayered controlled release pharmaceutical dosage form
PCT/US1995/003248 WO1995025506A1 (en) 1994-03-23 1995-03-16 Multilayered controlled release pharmaceutical dosage form

Publications (2)

Publication Number Publication Date
DE69518839D1 DE69518839D1 (de) 2000-10-19
DE69518839T2 true DE69518839T2 (de) 2001-02-22

Family

ID=22810614

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69518839T Expired - Lifetime DE69518839T2 (de) 1994-03-23 1995-03-16 Mehrschichtige pharmazeutische dosierungsform mit kontrollierter freigabe

Country Status (13)

Country Link
US (2) US5395626A (de)
EP (1) EP0760655B1 (de)
JP (1) JP4936577B2 (de)
AT (1) ATE196250T1 (de)
AU (1) AU703151B2 (de)
CA (1) CA2185893C (de)
DE (1) DE69518839T2 (de)
DK (1) DK0760655T3 (de)
ES (1) ES2151594T3 (de)
GR (1) GR3034971T3 (de)
PT (1) PT760655E (de)
WO (1) WO1995025506A1 (de)
ZA (1) ZA952343B (de)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
TR199701323T1 (xx) 1995-05-09 1998-02-21 Colorcon Limited Farmas�tik alttabakalar�n elektrostatik olarak kaplanmas� i�in toz kaplama kompozisyonu.
US7008668B2 (en) * 1995-05-09 2006-03-07 Phoqus Pharmaceuticals Limited Powder coating composition for electrostatic coating of pharmaceutical substrates
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
EP0811374A1 (de) 1996-05-29 1997-12-10 Pfizer Inc. Formulierung für ein Kombinationspräparat mit Cetirizin und Pseudoephedrin
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6238704B1 (en) * 1996-09-13 2001-05-29 Shionogi & Co., Ltd. Sustained-release preparation utilizing thermal change and process for the production thereof
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
GB9623634D0 (en) * 1996-11-13 1997-01-08 Bpsi Holdings Inc Method and apparatus for the coating of substrates for pharmaceutical use
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6156342A (en) * 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
DE29818454U1 (de) * 1998-10-15 1999-01-14 Euro Celtique Sa Opioid-Analgetikum
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
EP1228125A4 (de) * 1999-09-14 2009-09-02 Smithkline Beecham Corp Verfahren zur herstellung wässrig überzogener kügelchen
US6669954B2 (en) 2000-01-25 2003-12-30 John R. Crison Controlled release of drugs
EP1252887A4 (de) * 2000-01-27 2009-07-29 Mitsubishi Tanabe Pharma Corp Zubereitung mit verlängerter freisetzung und prozess zu deren herstellung
GB0002305D0 (en) * 2000-02-01 2000-03-22 Phoqus Limited Power material for electrostatic application
CA2400818C (en) 2000-02-24 2009-01-06 Advancis Pharmaceutical Corporation Antibiotic and antifungal compositions
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6623758B2 (en) * 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
AU2001257359A1 (en) 2000-04-27 2001-11-07 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
ATE274906T1 (de) * 2000-09-22 2004-09-15 Smb Technology Oral anzuwendende tramadolhaltige teilchen zur einmal täglichen verabreichung
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US7105174B2 (en) * 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
FR2821747B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Suspension de telithromycine a gout masque
CA2440588C (en) * 2001-03-13 2010-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US7157102B1 (en) * 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
GB2402895B (en) * 2003-06-18 2006-08-23 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
US8313775B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8313776B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
EP1651192A1 (de) * 2003-08-06 2006-05-03 Nirmal Mulye Pharmazeutische zusammensetzung mit einem wasserlöslichen arzneimittel
EP1653925A1 (de) * 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robustes pellet
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
JP2007513869A (ja) * 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
WO2005027878A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Delayed released dosage forms
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050142187A1 (en) * 2003-12-24 2005-06-30 Treacy Donald J.Jr. Enhanced absorption of modified release dosage forms
GB0330171D0 (en) * 2003-12-30 2004-02-04 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
GB0407312D0 (en) * 2004-03-31 2004-05-05 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US20060165769A1 (en) * 2004-09-30 2006-07-27 Hyatt John A Pharmaceutical formulations containing vitamin E TPGS molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
US20080038344A1 (en) * 2004-10-01 2008-02-14 Nippon Zoki Pharmaceutical Co., Ltd. Solid Pharmaceutical Preparation
US20060073205A1 (en) * 2004-10-04 2006-04-06 Kotoe Ohta Controlled release granules comprising porous silica core
WO2006058059A2 (en) 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588296A1 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
GB0427455D0 (en) * 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
ATE489079T1 (de) 2005-12-29 2010-12-15 Osmotica Kereskedelmi Es Szolgaltata Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
KR101455741B1 (ko) * 2006-03-30 2014-10-28 니폰 조키 세야쿠 가부시키가이샤 고형 의약 제제
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008002567A2 (en) * 2006-06-27 2008-01-03 Alza Corporation Methods of treating conditions by sustained release administration of benzimidazole derivatives
US7638344B2 (en) * 2006-06-28 2009-12-29 Surmodics, Inc. Active agent eluting matrices with particulates
BRPI0715959A2 (pt) * 2006-08-21 2013-07-30 Jubilant Organosys Ltd composiÇço farmacÊutica de liberaÇço modificada de cloridrato de bupropion
WO2008128140A1 (en) * 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Delivery device and method for forming the same
CN105534936B (zh) * 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
US20110217371A1 (en) * 2008-11-10 2011-09-08 Amorepacific Corporation Controlled-release microparticles and method of preparing same
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
US20100221328A1 (en) * 2008-12-31 2010-09-02 Wertz Christian F Sustained-release formulations
US20120277180A1 (en) 2009-09-30 2012-11-01 Vitapath Genetics, Inc Cofactors and Methods for Use for Individuals
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
EP2506709B2 (de) * 2009-12-02 2019-10-09 Adamas Pharmaceuticals, Inc. Amantadinzusammensetzungen und verfahren zu ihrer verwendung
KR101243938B1 (ko) * 2010-10-19 2013-03-19 이희엽 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
BR112014000895A2 (pt) 2011-07-15 2019-08-06 Nusirt Sciences Inc composições e métodos para modular rotas metabólicas
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
MX358211B (es) * 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
US9943517B2 (en) 2012-11-13 2018-04-17 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
AU2014207707B2 (en) 2013-01-15 2018-11-01 Nusirt Sciences, Inc. Treating pulmonary conditions
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
JP6550370B2 (ja) 2013-03-15 2019-07-24 ニューサート サイエンシーズ， インコーポレイテッド 脂質レベルを低下させるロイシンおよびニコチン酸
US11571390B2 (en) 2013-03-15 2023-02-07 Othemo Life Sciences, Inc. Abuse deterrent compositions and methods of use
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CA2939833A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016070696A1 (zh) * 2014-11-03 2016-05-12 杭州领业医药科技有限公司 达比加群酯或其盐的投药制剂及其制备方法
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
KR20180066113A (ko) * 2015-09-30 2018-06-18 웰즐리 파마슈티컬스 엘엘씨 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
EP3397253A1 (de) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit krämpfen
CN106176683B (zh) * 2016-08-31 2019-04-16 贵州益康制药有限公司 一种盐酸曲马多缓释胶囊及其制备方法和用途
US9707217B1 (en) 2017-02-03 2017-07-18 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
JP6482604B2 (ja) * 2017-06-22 2019-03-13 教裕 南郷 外皮内溶解型ニードル及びニードル装置
WO2019087084A1 (en) 2017-11-02 2019-05-09 Eman Biodiscoveries Sd. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB793808A (en) * 1954-07-22 1958-04-23 Frank Mario Bardani Sustained action pill
JPS5835110A (ja) * 1981-08-28 1983-03-01 Tetsuo Kato 徐放性マイクロカプセル
ZA838033B (en) * 1982-11-01 1984-06-27 Merrell Dow Pharma Sustained release solid dosage forms having non-uniform distribution of active ingredient
JPS5982311A (ja) * 1982-11-04 1984-05-12 Shionogi & Co Ltd セフアレキシン持効性製剤
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
US4826688A (en) * 1985-11-13 1989-05-02 501 Elan Corporation PLC. Controlled absorption pharmaceutical formulation
JPS62226926A (ja) * 1986-03-27 1987-10-05 Teisan Seiyaku Kk 持続性複合顆粒剤
JPH0236571B2 (ja) * 1986-04-11 1990-08-17 Otsuka Pharma Co Ltd Jizokuseiseizai
IT1197316B (it) * 1986-10-01 1988-11-30 Proter Spa Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico
JPS63319134A (ja) * 1987-06-22 1988-12-27 スリー　エス．テクノロジーズ　ベスローテン　ベノートスハップ 水供給用シ−ト
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
ES2064564T3 (es) * 1989-09-21 1995-02-01 American Cyanamid Co Sistema de liberacion pulsatil de dosis unitaria diaria de minociclina.
JP3090975B2 (ja) * 1991-05-13 2000-09-25 塩野義製薬株式会社 マルチリザ−バ−型徐放性顆粒剤およびその製法
ES2073301T3 (es) * 1991-05-20 1995-08-01 Marion Laboratories Inc Composicion multi-capa de liberacion controlada.
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient

Also Published As

Publication number Publication date
EP0760655A1 (de) 1997-03-12
AU1999595A (en) 1995-10-09
ES2151594T3 (es) 2001-01-01
PT760655E (pt) 2000-12-29
JPH09510709A (ja) 1997-10-28
WO1995025506A1 (en) 1995-09-28
DE69518839D1 (de) 2000-10-19
JP4936577B2 (ja) 2012-05-23
ZA952343B (en) 1996-09-23
GR3034971T3 (en) 2001-02-28
DK0760655T3 (da) 2000-11-13
EP0760655B1 (de) 2000-09-13
MX9604300A (es) 1998-05-31
ATE196250T1 (de) 2000-09-15
CA2185893A1 (en) 1995-09-28
US5474786A (en) 1995-12-12
CA2185893C (en) 2009-05-26
US5395626A (en) 1995-03-07
AU703151B2 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
DE69518839D1 (de) Mehrschichtige pharmazeutische dosierungsform mit kontrollierter freigabe
DE69817587D1 (de) Aus einer vielzahl von kleineinheiten aufgebaute brausedosisform
NO172422C (no) Fremgangsmaate for fremstilling av en medikamentholdig flerlagsgranul
DE69318415D1 (de) Arzneitablette, die befähigt ist, einen oder mehrere wirkstoffe mit unterschiedlichen abgaberaten freizusetzen
EP1123087A4 (de) Orales system zur verabreichung von gepulsten dosen eines arzneistoffs
DE69428862D1 (de) Linsenförmig pharmazeutische Tablette mit verzögerter Freigabe
ATE213629T1 (de) Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe
DE69729134D1 (de) Pharmazeutische Tablette geeignet zur Wirkstofffreisetzung in aufeinanderfolgenden und vorherbestimmbaren Zeiträumen
MX9706769A (es) Formas de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y un agente procinetico.
MXPA06000526A (es) Formas dobles de dosis de drogas, con separacion mejorada de estas drogas.
NO963202L (no) Misbruksresistente tabletter
DE69201793D1 (de) Mehrschichtige zubereitung mit kontrollierter freisetzung.
DE69425589D1 (de) Kombiniertes antipyretisches und analgetisches arzneimittel
AR036838A1 (es) Comprimido de varias capas de liberacion controlada, uso del mismo para la fabricacion de un medicamento util en el tratamiento de la fibromialgia y composicion farmaceutica que lo comprende.
ATE290854T1 (de) Carbamazepinformulierung mit verzögerter freigabe
ATE304844T1 (de) Entzündungshemmende pharmazeutische formulierungen
AR043070A1 (es) Sistema monolitico que contiene una o mas drogas, formado por tres capas con diferentes mecanismos de liberacion
KR100690518B1 (ko) 활성 물질을 펄스형으로 제어 전달하기 위한 다층 약제
GEP20022629B (en) Sustained-Release Microgranules Containing Diltiazem As The Active Principle and Gelatinous Capsule Containing the Same
TH19832EX (th) สูตรผสมทางเภสัชกรรมชนิดใหม่ที่ประกอบรวมด้วยเกลือแมกนีเซียมของออเมพราโซลที่มีรูปแบบทางกายภาพชนิดใหม่และวิธีสำหรับการผลิตเกลือนี้

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN